Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Ovarian Epithelial 1

Interventions

Magnetic Resonance Spectroscopy 270Specimen Handling 259pembrolizumab 235Cyclophosphamide 220Radiotherapy 208Nivolumab 171Cisplatin 162Carboplatin 150Biopsy 148Radiosurgery 130fludarabine 125Blood Specimen Collection 117Gemcitabine 113Paclitaxel 111Surveys and Questionnaires 109Standard of Care 106venetoclax 97Dexamethasone 96Bevacizumab 95Radiation 88Rituximab 84Capecitabine 82Cytarabine 79Oxaliplatin 77Doxorubicin 76Drug Therapy 75durvalumab 73Ipilimumab 72fludarabine phosphate 69atezolizumab 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Tinzaparin × 90 days × Clear all
NCT05284552 2026-05-11

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

University Hospital, Linkoeping

Phase 2 Recruiting
40 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡